Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al
about
Follicular lymphoma: 2012 update on diagnosis and managementIdiotype vaccination for Non-Hodgkin lymphomaHigh-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adultsAdverse effects of biologics: a network meta-analysis and Cochrane overviewIdiotype vaccination for Non-Hodgkin lymphomaChemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphomaUpdate on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphomaChemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphomaTargeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceuticalIdelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potentialObinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomasCritical appraisal of rituximab in the maintenance treatment of advanced follicular lymphomaThyroid lymphoma: recent advances in diagnosis and optimal management strategiesFollicular lymphoma: 2011 update on diagnosis and managementRole of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphomaFollicular lymphoma: 2014 update on diagnosis and managementTargeting CD19 in B-cell lymphoma: emerging role of SAR3419Treatment strategies for nodal and gastrointestinal follicular lymphoma: current status and future development.The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs EraSystemic Front Line Therapy of Follicular Lymphoma: When, to Whom and HowRole of Maintenance Rituximab (Rituxan) Therapy In the Treatment of Follicular LymphomaMeta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.Richter's transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group.Advance and stagnation in the treatment of patients with lymphoma and myeloma: Analysis using population-based cancer registry data in Japan from 1993 to 2006.Primary breast lymphoma: patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study.High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: promising results in marginal zone lymphoma.Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group.Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphomaCladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin's lymphoma (B-NHL) chemotherapy: a meta-analysis.Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignanciesIrinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.The clinical development of obinutuzumab for the treatment of follicular lymphoma.Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
P2860
Q22252956-35FD326C-17C6-4143-BC80-D302DB72AEEBQ24186272-C5791A03-0DEB-4F10-8EAF-02E7FFE62A9BQ24203878-873DD4DA-2911-4655-A91C-D12C6A70AA4EQ24234197-8AB33D72-6462-4BFF-9670-776A2C15031CQ24235281-1E9CC37B-F32A-4B30-BBEE-C113D333D9F5Q24243100-173FBFD9-DB3D-48F5-B38D-7BEC268FEA99Q24633710-312B1A63-F833-49AF-8538-9E1862794F66Q24633714-CD7C450F-F385-4A7A-AF3A-F4172E2815C0Q24681992-324EC11D-2617-4C03-8F3F-E6EEFA686BDDQ26747753-ACA94412-9281-4A75-BE55-21D0249A6B8FQ26751002-13801222-813C-4002-857F-3CFAFFB7131DQ26775837-5DF33A1A-DEAF-4E0C-AAD3-2AA7111E9ECEQ26827420-4B24C1B8-DEB9-4D51-826D-26640D7BBA41Q26851450-C47B6E62-8E38-4ECB-90D5-971937F27329Q27000310-B96E3D1D-703C-4C23-A852-15447307C63DQ27021850-4F7C298C-4695-4CE7-B145-86045C36D905Q27027562-F1F3EFAB-1642-4AE0-A810-724456738C31Q27693252-681436E2-BECB-4B2A-82FE-2DB6A8C61EF7Q28072397-6E1876D2-821F-4C75-BBEE-E0F0D6992BE0Q28073262-E472E66D-0AF0-49D3-B8D3-A6566A09C95FQ28972464-A9B879D8-7490-4F4D-A726-DE74201340AEQ30249335-711669F2-8E1D-47AE-8097-434446CD86CFQ30435188-A93367AA-062F-45FC-9910-20F89EE1A556Q30841807-04B81EA0-6ED3-476A-9060-0BD52053EC41Q30895580-0B28ED85-F9A4-4C62-9247-3633FE0493AEQ33326473-62A04B07-8590-46EA-B6BF-407710D21B7BQ33375798-34B5A198-D364-4D35-AFD7-867AB32F2CC5Q33378306-4C943E46-25F5-4561-A3CA-1BAF179F4C17Q33378309-568F3FE9-8B33-4549-86B0-1CB384C8EB39Q33385670-E832A282-9DF5-428C-A194-AAA643828BBAQ33392784-21B6F85E-6041-4B03-A173-6EB88190B8ECQ33416533-3A041E31-5497-4A00-A83D-8009A87D1BEBQ33416569-0C97371D-2833-4792-B488-75132F69DE0DQ33416982-21346684-6587-4CB6-9109-B1ED9311AB91Q33418964-7979C107-F75F-4113-8045-C9B26678752DQ33421964-E8F426B4-B250-42A1-B194-E5E14C06BBC9Q33422543-DF0DD7CB-4088-46E2-A450-B568F47BDEB7Q33442162-5ED09ABF-08BD-4374-A5E9-9D2C5A2D2E26Q33565265-8CC9A97A-F6CC-4BB1-8084-B1EADC2778F8Q33574197-44E18791-1145-4EE4-A9E0-1FFE3FF2CB02
P2860
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Frontline therapy with rituxim ...... ared with therapy with CHOP al
@en
Frontline therapy with rituxim ...... ared with therapy with CHOP al
@nl
type
label
Frontline therapy with rituxim ...... ared with therapy with CHOP al
@en
Frontline therapy with rituxim ...... ared with therapy with CHOP al
@nl
prefLabel
Frontline therapy with rituxim ...... ared with therapy with CHOP al
@en
Frontline therapy with rituxim ...... ared with therapy with CHOP al
@nl
P2093
P1433
P1476
Frontline therapy with rituxim ...... ared with therapy with CHOP al
@en
P2093
Ali Aldaoud
Bernd Metzner
Bernhard Wörmann
Eva Lengfelder
Hans-Edgar Reis
Harriet Harder
Hartmut Eimermacher
Jörg Schimke
Lorenz Trümper
Manfred Planker
P304
P356
10.1182/BLOOD-2005-01-0016
P407
P577
2005-08-25T00:00:00Z